Incannex Healthcare Ltd IXHL is soaring Tuesday on abnormally-high volume. The stock has been extremely volatile since the company released a preliminary analysis of data from its phase 2 clinical trial investigating its novel cannabinoid combination product, IHL-42X, for the treatment of obstructive sleep apnoea.
Related Link: Incannex Clinical Trial Shows Notable Reduction In The Apnoea Hypopnoea Index With Novel Cannabinoid Product
Incannex's average session volume is 5,768 over a 100-day period, according to data from Benzinga Pro. Tuesday's trading volume has already exceeded 325,000 at publication time.
Incannex is a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs.
IXHL Price Action: Icannex shares are making new 52-week highs after being halted several times during Tuesday's trading session.
The stock was up 210% at $71 at time of publication.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.